Integrated BioTherapeutics, Inc. (IBT) is a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. IBT's pipeline includes promising product candidates for several bacterial and viral infections. The bacterial program is focused on development of a multivalent vaccine for staphylococcal infections primarily by targeting a variety of toxins produced by S. aureus. IBT's antiviral pipeline includes candidate vaccines and antibody therapeutics for Hepatitis C Virus and viral hemorrhagic fevers caused by the deadly Ebola and Marburg viruses.
Located in Gaithersburg, Maryland, IBT has a close working relationship with many of the United States government agencies including the National Institute of Allergy and Infectious Diseases (NIAID/NIH), United States Army Medical Research Institute of Infectious Diseases (USAMRIID), National Cancer Institute (NCI), and the Department of Defense (DoD) and many technology based biotechnology and pharmaceutical companies.
In addition to the active anti-infective discovery pipline at IBT, the company also operates a CRO business named IBT Bioservices which provides state of the art infectious disease discovery and animal model testing services to industrial and academic clients.